Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Tremelimumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Astrazeneca's Triplet Combo Succeeds In Liver Cancer Subgroup
    Astrazeneca's Triplet Combo Succeeds In Liver Cancer Subgroup

    01 Jun 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/asco-astrazenecas-imfinzi-imjudo-duo-shines-earlier-stage-liver-cancer-win

    FIERCE PHARMA
    01 Jun 2026
    Share Share
    Combo Immunotherapy Cuts Kidney Cancer Recurrence Post-Surgery
    Combo Immunotherapy Cuts Kidney Cancer Recurrence Post-Surgery

    30 May 2026

    // ICR

    https://www.icr.ac.uk/about-us/icr-news/detail/combination-immunotherapy-significantly-reduces-kidney-cancer-recurrence-after-surgery

    ICR
    30 May 2026
    Share Share
    AstraZeneca to Share Phase 3 Cancer Data at ASCO 2026
    AstraZeneca to Share Phase 3 Cancer Data at ASCO 2026

    22 May 2026

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-to-showcase-phase-iii-data-at-asco-2026.html

    PRESS RELEASE
    22 May 2026
    Share Share
    VOLGA Trial: Imfinzi Plus EV Boosts Survival in Bladder Cancer
    VOLGA Trial: Imfinzi Plus EV Boosts Survival in Bladder Cancer

    14 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260514820907/en/Perioperative-IMFINZI-durvalumab-plus-neoadjuvant-EV-showed-statistically-significant-and-clinically-meaningful-improvements-in-event-free-survival-and-overall-survival-in-muscle-invasive-bladder-cancer-in-the-Phase-III-VOLGA-trial

    BUSINESSWIRE
    14 May 2026
    Share Share
    IMFINZI + IMJUDO Improves PFS in Early Liver Cancer
    IMFINZI + IMJUDO Improves PFS in Early Liver Cancer

    02 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260402535842/en/IMFINZI-durvalumab-IMJUDO-tremelimumab-actl-improves-PFS-in-early-liver-cancer

    BUSINESSWIRE
    02 Apr 2026
    Share Share
    AstraZeneca Pharma India to launch Tremelimumab
    AstraZeneca Pharma India to launch Tremelimumab

    23 Sep 2024

    // INDIANPHARMAPOST

    https://www.indianpharmapost.com/news/astrazeneca-pharma-india-to-launch-tremelimumab-16215

    INDIANPHARMAPOST
    23 Sep 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.